Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Threshold Issues Updated Results From Phase 2 Study Of TH-302 - Quick Facts

RELATED NEWS
Trade THLD now with 

Threshold Pharmaceuticals, Inc. (THLD: Quote) announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin.

In the single-arm Phase 2 component of the study, previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcomas were treated with TH-302 and doxorubicin for a maximum of six cycles. After six cycles, patients with stable disease, partial or complete responses, and with acceptable toxicity, were eligible to receive TH-302 maintenance therapy. Response was assessed using RECIST criteria.

In overall study population, results for the 91 patients in the Phase 2 component of the study include median progression free survival of 6.7 months, median overall survival of 21.5 months, one-year survival of 73% and two-year survival of 44% and overall best response of 36%.

The company also reported results for TH-302 single agent maintenance therapy population. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18 months. Overall best response was 54%.

Register
To receive FREE breaking news email alerts for Threshold Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.